Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

4Total
P 2 (4)

Trial Status

Recruiting3
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT02579967Phase 2Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NCT04339777Phase 2Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

NCT05787574Phase 2Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

NCT03663933Phase 2Active Not Recruiting

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Showing all 4 trials

Research Network

Activity Timeline